BioXcel Therapeutics Inc.

15.17+0.1700+1.13%Vol 408.78K1Y Perf -41.25%
Aug 11th, 2022 16:00 DELAYED
BID14.04 ASK16.10
Open15.06 Previous Close15.00
Pre-Market- After-Market15.17
 - -  - -%
Target Price
62.43 
Analyst Rating
Strong Buy 1.00
Potential %
311.54 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
23.02 
Earnings Rating
Strong Buy
Market Cap424.53M 
Earnings Date
9th Aug 2022
Alpha0.04 Standard Deviation0.35
Beta1.16 

Today's Price Range

14.7615.67

52W Range

8.8036.49

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-7.56%
1 Month
-2.26%
3 Months
40.99%
6 Months
-14.39%
1 Year
-41.25%
3 Years
83.66%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BTAI15.170.17001.13
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-1.20-1.35-12.50
Q01 2022-1.21-1.127.44
Q04 2021-1.18-0.9321.19
Q03 2021-1.08-0.9611.11
Q02 2021-1.03-1.11-7.77
Q01 2021-0.89-1.08-21.35
Q04 2020-0.87-0.870.00
Q03 2020-0.80-1.07-33.75
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.2010.45Positive
9/2022 QR-1.322.94Positive
12/2022 FY-4.670.85Positive
12/2023 FY-4.34-20.22Negative
Next Report Date-
Estimated EPS Next Report-1.20
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume408.78K
Shares Outstanding27.99K
Shares Float14.78M
Trades Count6.90K
Dollar Volume6.18M
Avg. Volume422.29K
Avg. Weekly Volume381.64K
Avg. Monthly Volume361.75K
Avg. Quarterly Volume523.47K

BioXcel Therapeutics Inc. (NASDAQ: BTAI) stock closed at 15.17 per share at the end of the most recent trading day (a 1.13% change compared to the prior day closing price) with a volume of 408.78K shares and market capitalization of 424.53M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. BioXcel Therapeutics Inc. CEO is Vimal Mehta.

The one-year performance of BioXcel Therapeutics Inc. stock is -41.25%, while year-to-date (YTD) performance is -25.38%. BTAI stock has a five-year performance of %. Its 52-week range is between 8.795 and 36.49, which gives BTAI stock a 52-week price range ratio of 23.02%

BioXcel Therapeutics Inc. currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 2.43, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -55.98%, a ROC of -58.40% and a ROE of -60.50%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from BioXcel Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.20 for the next earnings report. BioXcel Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioXcel Therapeutics Inc. is Strong Buy (1), with a target price of $62.43, which is +311.54% compared to the current price. The earnings rating for BioXcel Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioXcel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioXcel Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.26, ATR14 : 1.32, CCI20 : -56.27, Chaikin Money Flow : -0.05, MACD : 0.25, Money Flow Index : 43.33, ROC : -0.59, RSI : 39.49, STOCH (14,3) : 48.10, STOCH RSI : 0.42, UO : 53.51, Williams %R : -51.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioXcel Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701.

CEO: Vimal Mehta

Telephone: +1 475 238-6837

Address: 555 Long Wharf Drive, New Haven 06511, CT, US

Number of employees: 40

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

58%43%

Bearish Bullish

52%48%

TipRanks News for BTAI

Mon, 23 May 2022 10:25 GMT Bioxcel Therapeutics (BTAI) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits